Sort by
Refine Your Search
-
Listed
-
Category
-
Country
-
Program
-
Field
-
, physics, engineering and pharmacy to explore mechano-adaptation as a targetable vulnerability in the most aggressive brain cancer, Glioblastoma. The successful candidate will work closely with 3 other PhD
-
The University of North Carolina at Charlotte | Charlotte, North Carolina | United States | 6 days ago
portfolio, and elevate the overall brand experience. Develop and execute a comprehensive, multi-year external revenue growth strategy across all business verticals Set and surpass aggressive annual revenue
-
outbursts, verbal insults, and physical aggression. Position Details Additional Information Posting Category Healthcare Working Title Behavioral De-Escalation Program Manager (Posting for UNMC Emloyees Only
-
. Work with potentially aggressive individuals. Physically intervene in aggressive behaviors. Care for consumers with infectious diseases. Contact with consumers under a wide variety of circumstances
-
measurements and digital twins, enabling: to identify the presence of cavitating flow, to estimate the aggressiveness of the flow and machine wear, to define an appropriate operating strategy, to simulate
-
facility preferred. Must demonstrate ability to perform basic nursing care skills. Management of Aggressive Behaviors (MOAB) and Pro-Act certifications are required within 6 months of hire. Basic Life Safety
-
-growing neurodegenerative disease. Unfortunately, there is no treatment to halt or reverse disease progression. Loss-of-function of the lysosomal polyamine exporter ATP13A2 is causative for aggressive early
-
behaviors (e.g., grooming, food sharing, aggression, proximity) ⢠Set up cameras and monitoring equipment. Behavioral Experimentation (40%) ⢠Set up experimental arenas. ⢠Carry out behavioral trials
-
or crisis situations. May be exposed to clients exhibiting assaultive or aggressive behaviors. Generally pleasant working conditions in a clean, well-lighted, and quiet to moderately loud setting. Salary: A
-
leukaemia (AML). This three-year project will harness cytotoxic invariant Natural Killer T (iNKT) cells for precision targeting of AML, an aggressive leukaemia with poor survival outcomes. Building on strong